Elanco Animal Health (ELAN) Current Deferred Revenue (2017 - 2026)

Elanco Animal Health (ELAN) has 10 years of Current Deferred Revenue data on file, last reported at $400.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 25.39% year-over-year to $400.0 million; the trailing twelve-month figure through Mar 2026 stood at $400.0 million (up 25.39% YoY), and the FY2025 full-year result was $416.0 million, up 25.3% from the prior year.
• Current Deferred Revenue fell to $400.0 million in Q1 2026, from $416.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $416.0 million in Q4 2025 to a low of $284.0 million in Q2 2022.
• A 5-year average of $341.8 million and a median of $332.0 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue declined 10.27% in 2022 and gained 25.39% in 2026, its largest moves.
• Tracing ELAN's Current Deferred Revenue over 5 years: stood at $324.0 million in 2022, then increased by 13.27% to $367.0 million in 2023, then slipped by 9.54% to $332.0 million in 2024, then increased by 25.3% to $416.0 million in 2025, then declined by 3.85% to $400.0 million in 2026.
• Business Quant data shows ELAN's Current Deferred Revenue at $400.0 million in Q1 2026, $416.0 million in Q4 2025, and $376.0 million in Q3 2025.